SSA
BIAF icon

Schonfeld Strategic Advisors’s bioAffinity Technologies BIAF Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,628
Closed -$93.5K – 2624
2026
Q1 		$93.5K Buy
+1,628
New +$39.4K ﹤0.01% 1901

Other funds holding BIAF

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Schonfeld Strategic Advisors's BIAF Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of bioAffinity Technologies (BIAF) in Q2 2026, closing a stake of 1,628 shares — an estimated $93.5K sold.

Schonfeld Strategic Advisors first reported a position in BIAF in Q1 2026 and held it in 1 quarter. The position peaked at $93.5K in Q1 2026. 19 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining bioAffinity Technologies position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,628 bioAffinity Technologies shares in Q2 2026, an estimated $93.5K.
  • Schonfeld Strategic Advisors first reported a position in bioAffinity Technologies in Q1 2026 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's bioAffinity Technologies position peaked at $93.5K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.